BioMedNewsBreaks

WednesdayAug 05, 2026 1:17 pm

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) Combines Targeted Cancer Therapy, Nanotechnology and AI

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is pursuing an integrated approach to cancer drug development that combines three emerging areas: PNKP-targeted DNA damage response (“DDR”) inhibition, nanoparticle drug delivery and artificial intelligence. Its lead candidate, ONC010, pairs a PNKP inhibitor with a polymer micelle carrier intended to improve drug solubility, tumor accumulation and tolerability, while the company’s Inka Health subsidiary is developing the SynoGraph causal AI platform to support patient selection, clinical trial design and evidence generation. The company is advancing ONC010 through preclinical, manufacturing and IND-enabling activities, with plans…

Continue Reading

WednesdayAug 05, 2026 12:55 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Advances Telehealth Position Through Technology, Vertical Integration

Earth Science Tech (OTC: ETST) was featured in a recent article that discussed its positioning in the growing telehealth and healthcare markets through strategic investments, vertical integration and proprietary technology. Through subsidiaries such as DOConsultations LLC and Las Villas Health Care Inc., the company provides online and brick-and-mortar telehealth services focused on wellness and direct-to-patient delivery, while also targeting the expanding peptide therapy market. ETST’s in-house IT capabilities and custom technology infrastructure are designed to provide a competitive advantage by improving operational efficiency and margins across its divisions. As the company continues expanding its technology and healthcare offerings, its integrated platform…

Continue Reading

WednesdayAug 05, 2026 12:26 pm

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Publishes Peer-Reviewed Capture-Seq Study 

VolitionRx Limited (NYSE American: VNRX) announced the publication of the first peer-reviewed paper detailing its proprietary Capture-Seq liquid biopsy technology, which the company said is the first to isolate and analyze more than 99% pure circulating tumor-derived DNA ("ctDNA"). According to the publication, the technology addresses a longstanding challenge in liquid biopsy by separating cancer-derived DNA from the large background of healthy cell-free DNA, creating highly enriched tumor DNA datasets for cancer detection and monitoring. Volition said it is conducting technical evaluations with potential licensing partners and estimates the technology addresses annual market opportunities of approximately $23 billion for multi-cancer early detection and more than $13 billion for…

Continue Reading

TuesdayAug 04, 2026 1:25 pm

BioMedNewsBreaks — SRX Global Inc. (NYSE American: SRXH) Acquires Stake in Vistagen Therapeutics 

SRX Global (NYSE American: SRXH) announced that it has acquired a stake in Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company developing intranasal neuroscience therapies based on its proprietary pherine platform. SRX said the investment aligns with its strategy of creating long-term shareholder value through investments in high-conviction operating companies and strategic assets. SRX said it believes Vistagen shares are undervalued and intends to engage constructively with the company's leadership team and board of directors to discuss opportunities to unlock shareholder value. To view the full press release, visit https://ibn.fm/VFyBI About SRX Global Inc. SRX Global is an AI-driven platform focused on generating long-term shareholder value through investments in high-conviction…

Continue Reading

MondayAug 03, 2026 9:50 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Present at OTCQB Virtual Investor Conference

Oncotelic Therapeutics (OTCQB: OTLC) announced that CEO and Chairman Dr. Vuong Trieu will present at the OTCQB Virtual Investor Conference on Aug. 6, 2026, at 2:30 p.m. ET, where investors will have the opportunity to participate in a live question-and-answer session. The company will highlight recent progress, including advancement of its Phase 1b intravenous Everolimus (Sapu003) trial to the next dose cohort, expansion of European clinical sites, validation of its Deciparticle(TM) platform through peer-reviewed publications, scalable cGMP manufacturing capabilities and continued development of its AI-driven drug discovery, robotics and nanomedicine platforms. To view the full press release, visit https://ibn.fm/fGHUt About…

Continue Reading

FridayJul 31, 2026 3:53 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances Regenerative Solution for Major Unmet Need in Cartilage Repair

Regentis Biomaterials (NYSE American: RGNT) was featured in a recent article that discussed its efforts to advance GelrinC, a potentially first-in-class, off-the-shelf cartilage regeneration platform, and the company’s broader mission to establish a new standard of care in cartilage repair. “Regentis is developing regenerative biomaterial technology as healthcare shifts toward therapies designed to restore damaged tissue rather than simply manage symptoms. With cartilage defects affecting hundreds of thousands of patients each year and contributing to pain, reduced mobility, and degenerative joint disease, the company is targeting one of orthopedic medicine’s largest unmet needs,” reads the article. “GelrinC’s commercial potential is rooted in…

Continue Reading

FridayJul 31, 2026 3:44 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances MS Imaging Study with Encouraging Preliminary Results

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has reached the halfway point in patient enrollment for its pilot MS imaging study with Massachusetts General Hospital, with preliminary PET imaging data showing encouraging signals in acute MS lesions. The novel imaging technique is designed to distinguish demyelinated nerve fibers that may still be viable from permanent nerve damage, potentially offering a more precise way to measure myelin loss and repair. “These findings are directly relevant to Lucid-MS, the company’s investigational compound designed to inhibit demyelination by targeting the enzyme PAD2, which…

Continue Reading

ThursdayJul 30, 2026 12:58 pm

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Closes CAD$5 Million Private Placement to Advance Oncology Programs

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced the closing of its previously announced non-brokered private placement with Sorbie Bornholm LP and Sorbie Investments LLP, representing a notional subscription amount of approximately CAD$5 million. The financing included the issuance of 7.94 million units at a notional price of CAD$0.63 per unit, with each unit consisting of one common share and one warrant exercisable at CAD$0.77 for three years. The proceeds will be made available to the company through an 18-month sharing arrangement tied to the volume-weighted…

Continue Reading

ThursdayJul 30, 2026 12:23 pm

BioMedNewsBreaks — Earth Science Tech Inc.’s (ETST) Vertical Integration Drives Revenue Growth, Product Expansion

Earth Science Tech (OTC: ETST) is leveraging a diversified, vertically integrated business model spanning pharmaceuticals, telemedicine, retail and real estate. Through subsidiaries including Peak Curative, RxCompound and Mister Meds, the company connects telemedicine consultations, compounding pharmacies and medication fulfillment within an end-to-end healthcare ecosystem. Its MOCTeledoc platform also provides B2B technology and clinical staffing solutions, allowing ETST to generate revenue by supporting other digital health companies while expanding its own reach. The integrated model supports product development and diversification, contributing to fiscal 2026 revenue growth of 8%, alongside increases in gross profit and net income. To view the full article, visit https://ibn.fm/I1F0R…

Continue Reading

ThursdayJul 30, 2026 11:54 am

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Highlights Growing Clinical Evidence Supporting Nu.Q NETs Test 

VolitionRx Limited (NYSE American: VNRX) highlighted a growing body of clinical and scientific evidence supporting its Nu.Q NETs assay as a biomarker for sepsis and other diseases associated with NETosis, while releasing an educational video featuring Critical Care Lead and Medical Consultant Dr. Andrew Retter. The company said multiple studies have shown its Nu.Q H3.1 test can distinguish sepsis from non-infectious inflammation, correlate with disease severity and provide strong prognostic value for outcomes including organ failure and mortality. Volition said most of the supporting research has been peer reviewed and published, with experts noting the consistency of findings across multiple countries and patient populations. The company believes its low-cost nucleosome quantification technology…

Continue Reading